News12/11/2024
Formation Bio and collaborators introduce Muse
Formation Bio, Inc. →Formation Bio, Sanofi and OpenAI introduced Muse, an AI tool intended to improve clinical-trial patient recruitment. The tool analyzes scientific literature, real-world evidence and patient-population information, then helps prepare recruitment strategies and materials. It was the first announced output of the companies’ collaboration. Formation Bio and Sanofi planned to use it in upcoming trials, with Sanofi leading an initial multiple-sclerosis Phase 3 deployment. The release describes intended capabilities and deployment plans; it does not establish independently measured clinical outcomes or regulatory approval of the software.